Limonene

SMITHS FALLS, ON, Jan. 24, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading diversified cannabis company, today announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. "In addition to launching new flower products, we're making it easier to access CBD and minor cannabinoids in convenient oil and softgel formats to support wellness-minded consumers looking to start the year feeling their best," said Dave Paterson, President, Canada, Canopy Growth. "For our medical cannabis consumers, we're proud to continue delivering the variety and convenience that the Spectrum Therapeutics store is synonymous for thanks to new pre-rolls from 7ACRES and the Spectrum Reserve." Tweed Lemon Meringue Pie flower For consumers not wanting to compromise quality for quantity, Tweed Lemon Meringue Pie is being served up fresh in a large format 28g package. Packed with sativa whole cannabis flower which has been derived from the Lemon Skunk and Cookies 'n' Cream lineage, it features terpenes a-Pinene, Myrcene and Limonene. Tweed's Lemon Meringue Pie boasts lemon, citrus and nutty vanilla aromas, is hang-dried, and comes in with a 23-29% THC range. Grown in our Kincardine, Ontario facility and packaged with a Boveda humidity control pack to ensure freshness, this new flower offering is full of flavour just like lemon meringue should be. 7ACRES Jack Haze pre-rolls 7ACRES Jack Haze pre-rolled joints are arriving in a 0.5gx14 large pack and feature the famous sativa-dominant cultivar with a unique combination of sweet citrus, crisp pine, and warm spice notes. With a range of 17-23% THC and a max CBD potency of 25%, 7ACRES Jack Haze was the result of a large-scale genetic selection program with the goal of finding this novel sativa expression. This phenotype stood out among the rest as it possessed both the sweet haze notes characteristic of a haze cultivar, along with a distinct spice aroma. Spectrum Reserve pre-rolls Exclusive for medical cannabis customers, Spectrum Therapeutics is extending its Spectrum Reserve collection with Alien Breath and (GG#4 x Mendo Breath) pre-roll joints. Coming in a 0.5gx10 large pack of pre-rolls, this hybrid strain delivers a high 22-28% THC range. The flower's berry, fruity, nutty, sour, and chemical notes derive from its Alien Breath and (GG#4 x Mendo Breath) lineage and its terpenes include 3.5% β-Caryophyllene, 6% D-Limonene, 6.5% Beta Myrcene, and 10% Pinene (Alpha & Beta). With consumer needs top of mind, Tweed has also introduced four new products featuring CBD and minor cannabinoids in both oil and softgel formats. Tweed CBD:CBG 4:1 Oil A newly formulated cannabis oil arriving in a 30mL bottle, Tweed CBD:CBG 4:1 is designed to pair with well-being focused daily routines and provides 100 mg/g CBD and 25 mg/g CBG. Tweed CBD:CBG 6:1 Softgels For those who prefer the convenience and portability of the softgel format, Tweed CBD:CBG 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBG. Tweed CBD:CBN 4:1 Oil Coming in a 30mL oil format, the Tweed CBD:CBN 4:1 oil offering is designed to become part of a nightly routine and delivers 100 mg/g CBD and 25 mg/g CBN. Tweed CBD:CBN 6:1 Softgels Another win for those who prefer the convenience of softgels, Tweed CBD:CBN 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBN. Tweed oil and softgel products are made with non-GMO, coconut derived MCT oil and blended cannabis extracts. All Tweed offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. 7ACRES and Spectrum products are available for purchase online at spectrumtherapeutics.com. For more information, please visit Tweed and Spectrum Therapeutics. Disclaimer: Terpene amounts may vary on a per-lot basis due to the natural variability of cannabis plants. THC and CBD ranges may vary. See product packaging for accurate levels. Everyone experiences cannabis differently. About Canopy Growth Canopy Growth is a leading North American cannabis and consumer packaged goods ("CPG") company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth's CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with principal operations in densely populated states across the Northeast, as well as Wana Brands, a leading cannabis edible brand in North America, and Jetty Extracts, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Beyond our world-class products, Canopy Growth is leading the industry forward through a commitment to social equity, responsible use, and community reinvestment—pioneering a future where cannabis is understood and welcomed for its potential to help achieve greater wellbeing and life enhancement. For more information visit References to information included on, or accessible through, our website do not constitute incorporation by reference of the information contained at or available through our website, and you should not consider such information to be part of this press release. SOURCE Canopy Growth Corporation

A research team has uncovered a previously undetected mechanism in mice -- starring the genetic molecule RNA -- that could explain how each sensory cell, or neuron, in mammalian noses becomes tailored to detect a specific odor chemical. The mammalian nose is a work of evolutionary art. Its millions of nerve cells, each tailored with just one of thousands of specific odor-chemical receptors encoded in the genome, can collectively distinguish a trillion distinct scents. Those sensations, in turn, inform many behaviors, from assessing food options to discerning friends from foes to sparking memories. Today, in the journal Nature, a research team led by scientists at Columbia's Zuckerman Institute describes a previously undetected mechanism in mice -- starring the genetic molecule RNA -- that could explain how each sensory cell, or neuron, in mammalian noses becomes tailored to detect a specific odor chemical. For example, there are sensory neurons in our noses that bear receptors uniquely tuned to detect ethyl vanillin, the main odorant in vanilla, and other cells with receptors for limonene, lemon's signature odorant. "How sensory cells in the nose make their receptor choices has been one of the most vexing mysteries about olfaction," said Stavros Lomvardas, PhD, a Roy and Diana Vagelos Professor and Chair of Biochemistry and Molecular Biophysics and Herbert and Florence Irving Professor of Neuroscience at Columbia's Zuckerman Institute and the Vagelos College of Physicians and Surgeons, and corresponding author on the paper. "Now, the story behind our sense of smell, or olfaction, is becoming clearer, and also more dramatic." The sense-refining drama he is referring to unfolds entirely within the minuscule confines of each olfactory neuron's nucleus, where the cell's chromosomes and genes reside. There, in a Squid Games-style, winner-takes-all competition, a developing cell's myriad olfactory receptor genes vie with each other in a process that winnow them down, in stages, first to handful of finalists and then to a single winner. The prevailing gene is the one that determines the cell's odorant sensitivity. In their study, Dr. Lomvardas and his team uncover details of the final stage of this process when the winner emerges from the finalist genes. "It's basically a battle between a 1000 contenders," said Ariel Pourmorady, the paper's first author and an M.D.-Ph.D. candidate at the Zuckerman Institute in the Lomvardas lab. The action is exceedingly complex and involves a dizzying cast of molecular characters. Playing roles that either dial up or down each gene's ability to produce olfactory receptors are a variety of gene-regulating molecules. By gathering into various alliances within the genome, these molecular players help turn specific genes on or off. Also in the fray is another set of molecular hubs that reshape portions of the genome in ways that favor specific receptor genes. When his team first observed these in the genome in 2014, Dr. Lomvardas dubbed them "Greek Islands" because they reminded him of islands in the Aegean Sea. "It turns out that the genome has a certain spatial organization in the nucleus and changes in this structure are pivotal when it comes to which genes are expressed into proteins, like olfactory receptors," said Pourmorady. "We are learning just how important this process is within maturing olfactory cells." In their new Nature paper, the researchers summon a trove of data from mouse studies pointing toward RNA as the linchpin molecule in the olfactory system's gene-choosing mechanism. RNA is most known as the go-between molecule that translates the genetic code embodied in DNA into protein molecules with specific cellular jobs, like detecting odorants. Using sophisticated techniques for analyzing changes in genome structure as cells mature, however, the researchers say their evidence points to a pivotal second role for the RNA. "It looks like the RNA the cell makes during gene expression also is altering the genome's architecture in ways that bolster the expression of one olfactory receptor gene while also shutting down all the others," Pourmorady said. Big gaps in this genome-controlling story remain, but the researchers say the outline is becoming more defined. It starts with maturing olfactory cells, which initially express many receptor genes at those genomic hubs where gene-regulating molecules and complexes, including Greek Islands, converge. Then the RNA winnows the contending olfactory-receptor genes down to one. The particular hub in each cell where the molecular stars align to produce the highest amount of RNA wins the competition. At this hub, receptor-gene expression soars. But, like a slinky saboteur, RNA from that same hub may wind its way to all the other hubs. In those locations, the RNA causes shape changes in the genome that shut down gene expression. The result is a nose's worth of mature olfactory neurons, each of which bears on its surface only one odorant receptor. "We are reaching the edge of science fiction when it comes to the molecular and genomic details we now can observe inside a single cell's nucleus," said Dr. Lomvardas. "We need to keep going back in to figure out the rest of this olfaction puzzle."